Matches in SemOpenAlex for { <https://semopenalex.org/work/W2737220576> ?p ?o ?g. }
Showing items 1 to 96 of
96
with 100 items per page.
- W2737220576 abstract "574 Background: Biomarkers of bone turnover, including urine N-telopeptide (uNTx) and serum C-telopeptide (sCTx) reflect tumor-related bone breakdown and have been used as surrogate measures of response to therapy in trials. Vascular endothelial growth factor (VEGF) levels correlate with extent of bone metastases (BM). We assessed whether vandetanib, an inhibitor of VEGF, epidermal growth factor receptor and RET signalling, improved uNTx response when added to fulvestrant (F) in patients with BM. Methods: Postmenopausal patients with bone only, or bone predominant, hormone receptor positive MBC were randomised to F (500mg IM day 1, 14, 28, then monthly) with either vandetanib (100mg PO OD) (FV) or placebo (FP) until progression. The primary objective was uNTx response (>30% reduction from baseline). uNTx was collected at baseline, weekly to wk 4, at wk 12 and then every 12 wks. Secondary objectives included PFS, OS, RECIST response, pain and toxicity. Results: 61 patients were allocated to FV and 68 to FP. Median age was 59. 18% had received 1 prior chemotherapy regime and 73% prior endocrine therapy for MBC. uNTx response (n=124 pts) was 64% for FV vs. 52% for FP (p=0.20). No difference was detected between groups for median PFS; 6 months for FV vs. 4.8 months for FP, HR=0.93 (95% CI: 0.64 to 1.36). 16 patients died in FV arm vs. 21 in the FP arm, HR=0.71 (95% CI: 0.37 to 1.36). For those patients with measurable disease, clinical benefit rates were 41% and 43%, respectively, p=1.00. Serious adverse events were similar, 3.3% for FV vs. 5.9% for FP. Elevated baseline uNTx (>65 nM BCE/mmol Cr) was prognostic for PFS, HR=1.62 (95% CI: 1.08 to 2.43 and for mortality, HR= 2.4 (95% CI: 1.2 to 4.6). In an exploratory analysis uNTx was predictive of responsiveness to FV for PFS, HR=0.60 when uNTx >65 vs. HR=1.37 when uNTx <65, P = 0.025 for interaction. Conclusions: The addition of vandetanib to F did not improve biomarker response, PFS or OS compared to F alone in patients with bone predominant disease. Exploratory analyses confirmed that baseline bone turnover markers are prognostic for PFS and OS. Clinical trial information: NCT00811369." @default.
- W2737220576 created "2017-07-31" @default.
- W2737220576 creator A5002547008 @default.
- W2737220576 creator A5013493617 @default.
- W2737220576 creator A5033936929 @default.
- W2737220576 creator A5047689900 @default.
- W2737220576 creator A5049493074 @default.
- W2737220576 creator A5049907389 @default.
- W2737220576 creator A5050942494 @default.
- W2737220576 creator A5056387446 @default.
- W2737220576 creator A5065930194 @default.
- W2737220576 creator A5079164469 @default.
- W2737220576 creator A5089808394 @default.
- W2737220576 date "2013-05-20" @default.
- W2737220576 modified "2023-09-23" @default.
- W2737220576 title "Randomized phase II placebo-controlled trial of fulvestrant plus vandetanib in postmenopausal women with bone only or bone predominant, hormone receptor-positive metastatic breast cancer (MBC): OCOG Zamboney study—NCT00811369." @default.
- W2737220576 doi "https://doi.org/10.1200/jco.2013.31.15_suppl.574" @default.
- W2737220576 hasPublicationYear "2013" @default.
- W2737220576 type Work @default.
- W2737220576 sameAs 2737220576 @default.
- W2737220576 citedByCount "2" @default.
- W2737220576 countsByYear W27372205762013 @default.
- W2737220576 countsByYear W27372205762016 @default.
- W2737220576 crossrefType "journal-article" @default.
- W2737220576 hasAuthorship W2737220576A5002547008 @default.
- W2737220576 hasAuthorship W2737220576A5013493617 @default.
- W2737220576 hasAuthorship W2737220576A5033936929 @default.
- W2737220576 hasAuthorship W2737220576A5047689900 @default.
- W2737220576 hasAuthorship W2737220576A5049493074 @default.
- W2737220576 hasAuthorship W2737220576A5049907389 @default.
- W2737220576 hasAuthorship W2737220576A5050942494 @default.
- W2737220576 hasAuthorship W2737220576A5056387446 @default.
- W2737220576 hasAuthorship W2737220576A5065930194 @default.
- W2737220576 hasAuthorship W2737220576A5079164469 @default.
- W2737220576 hasAuthorship W2737220576A5089808394 @default.
- W2737220576 hasConcept C121608353 @default.
- W2737220576 hasConcept C126322002 @default.
- W2737220576 hasConcept C142724271 @default.
- W2737220576 hasConcept C143998085 @default.
- W2737220576 hasConcept C168563851 @default.
- W2737220576 hasConcept C170493617 @default.
- W2737220576 hasConcept C204787440 @default.
- W2737220576 hasConcept C23589133 @default.
- W2737220576 hasConcept C27081682 @default.
- W2737220576 hasConcept C2775930923 @default.
- W2737220576 hasConcept C2777783956 @default.
- W2737220576 hasConcept C2780333294 @default.
- W2737220576 hasConcept C2780482068 @default.
- W2737220576 hasConcept C42362537 @default.
- W2737220576 hasConcept C530470458 @default.
- W2737220576 hasConcept C71924100 @default.
- W2737220576 hasConcept C84606932 @default.
- W2737220576 hasConceptScore W2737220576C121608353 @default.
- W2737220576 hasConceptScore W2737220576C126322002 @default.
- W2737220576 hasConceptScore W2737220576C142724271 @default.
- W2737220576 hasConceptScore W2737220576C143998085 @default.
- W2737220576 hasConceptScore W2737220576C168563851 @default.
- W2737220576 hasConceptScore W2737220576C170493617 @default.
- W2737220576 hasConceptScore W2737220576C204787440 @default.
- W2737220576 hasConceptScore W2737220576C23589133 @default.
- W2737220576 hasConceptScore W2737220576C27081682 @default.
- W2737220576 hasConceptScore W2737220576C2775930923 @default.
- W2737220576 hasConceptScore W2737220576C2777783956 @default.
- W2737220576 hasConceptScore W2737220576C2780333294 @default.
- W2737220576 hasConceptScore W2737220576C2780482068 @default.
- W2737220576 hasConceptScore W2737220576C42362537 @default.
- W2737220576 hasConceptScore W2737220576C530470458 @default.
- W2737220576 hasConceptScore W2737220576C71924100 @default.
- W2737220576 hasConceptScore W2737220576C84606932 @default.
- W2737220576 hasLocation W27372205761 @default.
- W2737220576 hasOpenAccess W2737220576 @default.
- W2737220576 hasPrimaryLocation W27372205761 @default.
- W2737220576 hasRelatedWork W1752683316 @default.
- W2737220576 hasRelatedWork W1887639305 @default.
- W2737220576 hasRelatedWork W1963589421 @default.
- W2737220576 hasRelatedWork W1971400130 @default.
- W2737220576 hasRelatedWork W1994839381 @default.
- W2737220576 hasRelatedWork W2024497659 @default.
- W2737220576 hasRelatedWork W2038250246 @default.
- W2737220576 hasRelatedWork W2078210065 @default.
- W2737220576 hasRelatedWork W2245317228 @default.
- W2737220576 hasRelatedWork W2247411625 @default.
- W2737220576 hasRelatedWork W2335252455 @default.
- W2737220576 hasRelatedWork W2471750430 @default.
- W2737220576 hasRelatedWork W2561824384 @default.
- W2737220576 hasRelatedWork W2605489431 @default.
- W2737220576 hasRelatedWork W2621523119 @default.
- W2737220576 hasRelatedWork W2895041664 @default.
- W2737220576 hasRelatedWork W2897693137 @default.
- W2737220576 hasRelatedWork W2947797714 @default.
- W2737220576 hasRelatedWork W2963711437 @default.
- W2737220576 hasRelatedWork W3146598657 @default.
- W2737220576 isParatext "false" @default.
- W2737220576 isRetracted "false" @default.
- W2737220576 magId "2737220576" @default.
- W2737220576 workType "article" @default.